Literature DB >> 19539340

Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.

Evelien M Bunnik1, Marit J van Gils, Marilie S D Lobbrecht, Linaida Pisas, Ad C van Nuenen, Hanneke Schuitemaker.   

Abstract

The conserved nature of the epitopes of the four broadly neutralizing antibodies (BNAbs), b12, 2G12, 2F5, and 4E10, may imply that the sensitivity of HIV-1 for these BNAbs remains fairly constant over the course of infection. Here, we demonstrate that viruses isolated early during the course of infection were mostly sensitive to HIVIg and antibody neutralization, although variation was observed in neutralization sensitivity of coexisting viruses to the different antibodies as well as between viruses from different patients. HIV-1 resistance to HIVIg developed relatively early during follow-up in three out of five patients, while early, b12 sensitive viruses in three out of five patients were replaced by b12 resistant variants relatively late in infection. In contrast, viruses generally remained sensitive to 2F5 and 4E10 neutralization over the course of infection, although 2F5 and/or 4E10 resistant variants did emerge later in infection in four out of five patients. In most patients, HIV-1 resistance to 2F5 or 4E10 did not correlate with mutations at critical amino acid positions in their defined epitopes. Viruses resistant to 2G12-mediated neutralization were present throughout the course of infection. As viral resistance against BNAb-mediated neutralization generally developed when autologous serum neutralizing activity had faded, it seems unlikely that these changes are driven by escape from autologous humoral immunity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19539340     DOI: 10.1016/j.virol.2009.05.028

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic.

Authors:  Zelda Euler; Evelien M Bunnik; Judith A Burger; Brigitte D M Boeser-Nunnink; Marlous L Grijsen; Jan M Prins; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-05-11       Impact factor: 5.103

Review 2.  Role of humoral immunity in host defense against HIV.

Authors:  Linda L Baum
Journal:  Curr HIV/AIDS Rep       Date:  2010-02       Impact factor: 5.071

3.  Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques.

Authors:  Fan Wu; Ilnour Ourmanov; Takeo Kuwata; Robert Goeken; Charles R Brown; Alicia Buckler-White; Ranjini Iyengar; Ronald Plishka; Scott T Aoki; Vanessa M Hirsch
Journal:  J Virol       Date:  2012-06-13       Impact factor: 5.103

4.  Dimeric 2G12 as a potent protection against HIV-1.

Authors:  Xin M Luo; Margarida Y Y Lei; Rana A Feidi; Anthony P West; Alejandro Benjamin Balazs; Pamela J Bjorkman; Lili Yang; David Baltimore
Journal:  PLoS Pathog       Date:  2010-12-16       Impact factor: 6.823

5.  Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge.

Authors:  Marie Borggren; Johanna Repits; Jasminka Sterjovski; Hannes Uchtenhagen; Melissa J Churchill; Anders Karlsson; Jan Albert; Adnane Achour; Paul R Gorry; Eva Maria Fenyö; Marianne Jansson
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

Review 6.  Why Does the Molecular Structure of Broadly Neutralizing Monoclonal Antibodies Isolated from Individuals Infected with HIV-1 not Inform the Rational Design of an HIV-1 Vaccine?

Authors:  Marc H V Van Regenmortel
Journal:  AIMS Public Health       Date:  2015-05-06

7.  A nonparametric procedure for defining a new humoral immunologic profile in a pilot study on HIV infected patients.

Authors:  Chiara Brombin; Lorenzo Diomede; Daniela Tudor; Anne Sophie Drillet; Claudia Pastori; Elena Poli; Agostino Riva; Caterina Uberti-Foppa; Massimo Galli; Clelia Di Serio; Morgane Bomsel; Lucia Lopalco
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

8.  Variations in the Biological Functions of HIV-1 Clade C Envelope in a SHIV-Infected Rhesus Macaque during Disease Progression.

Authors:  For Yue Tso; Levon Abrahamyan; Shiu-Lok Hu; Ruth M Ruprecht; Charles Wood
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

9.  Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection.

Authors:  Antoine Chaillon; Martine Braibant; Stéphane Hué; Samia Bencharif; David Enard; Alain Moreau; Assia Samri; Henri Agut; Francis Barin
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

10.  HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans.

Authors:  Delphine C Malherbe; Rogier W Sanders; Marit J van Gils; Byung Park; Michelle M Gomes; Hanneke Schuitemaker; Susan Barnett; Nancy L Haigwood
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.